Research Paper Advance Articles

Figure 5. Analysis of IC50 for different drugs in pan-cancer cell lines and drug sensitivity in HNSC from various databases. (A) Comparison of IC₅₀ of PD-0332991, Sorafenib, PHA-665752, L-685458, TAR684, Nutlin-3, TKI258, Panobinostat, ZD-6474, Paclitaxel, Topotecan, 17-AAG, RAF265, Nilotinib, PF2341066, AZD0530, PD-0325901, Lapatinib, PLX4720, Irinotecan, LBW242, AZD6244, Erlotinib and AEW541 between groups stratified by ALKBH7 expression levels. (B) Correlation between ALKBH7 expression and IC₅₀ of TAK-733, ARRT-704, Pluripotin, Cobimetinib, Trametinib, Cladribine, SNS-314, Methylprednisolone and PD-0325901 in pan-cancer. (C) Correlation between the expression of ALKBH7 and drug sensitivity/resistance via 3 public drug sensitivity databases (PRISM, GDSC and CTRP). ^*p < 0.05, ^**p < 0.01, ^***p < 0.001, ^****p < 0.0001.